Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 3 Jan 2013 |
| Articles of Association for Genmab A/S | 18 Dec 2012 |
| Genmab Unveils A New Antibody Technology Platform: HexaBody | 17 Dec 2012 |
| Genmab Reaches Third Milestone in Lundbeck Collaboration | 13 Dec 2012 |
| Genmab Reduces Fair Value of Minnesota Manufacturing Facility to Zero, Moves Sale into 2013 and Updates 2012 Guidance | 13 Dec 2012 |